Filtered By:
Cancer: Leukemia
Management: WHO

This page shows you your search results in order of date.

Order by Relevance | Date

Total 237 results found since Jan 2013.

Interleukin-37 gene expression is down-regulated in patients with acute myeloid leukemia and shown to be affected by CD14 and HLA-DR immunophenotypes
In conclusion, IL37 mRNA expression was down-regulated in AML patients, especially females, and those with the FAB M4 type and the WHO PML-RARA type. This expression may be affected by the immunophenotypic markers CD14 and HLA-DR.PMID:37716188 | DOI:10.1016/j.cyto.2023.156368
Source: Cytokine - September 16, 2023 Category: Molecular Biology Authors: Mustafa A Bashi Ali H Ad'hiah Source Type: research

Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms
CONCLUSIONS: This study confirms that a majority of cases are classified similarly using the 2 systems. Given the overall similarity of the systems, future harmonization of the classifications should be pursued to avoid confusion and multiple diagnoses.PMID:37587830 | DOI:10.1093/ajcp/aqad097
Source: American Journal of Clinical Pathology - August 17, 2023 Category: Pathology Authors: Saurav Chopra Nathanael G Bailey Source Type: research

Immunophenotype distinctions of CEBPA mutation subtypes in acute myeloid leukemia
CONCLUSIONS: AML with CEBPAdmBZIP , CEBPAdm-woBZIP , and CEBPAsmBZIP shared similar immunophenotypic profiles, whereas profoundly differed from the CEBPAsm-woBZIP and CEBPAwt AML.PMID:37334560 | DOI:10.1111/ijlh.14124
Source: International Journal of Laboratory Hematology - June 19, 2023 Category: Hematology Authors: Qiaoxue Liu Ling Qi Miao Yang Xue Zhang Fei Li Hui Wei Jianxiang Wang Source Type: research

Updates in Immunohistochemistry for Hematopoietic and Lymphoid Neoplasms
CONCLUSIONS.—: The practicing hematopathologist requires knowledge of the ever-expanding repertoire of immunohistochemistry for the diagnosis and treatment of hematolymphoid neoplasia. New markers presented in this article help to complete our understanding of disease, diagnosis, and management.PMID:37270801 | DOI:10.5858/arpa.2022-0465-RA
Source: Archives of Pathology and Laboratory Medicine - June 4, 2023 Category: Laboratory Medicine Authors: Haluk Kavus Yi Ding Mary Dhesi Source Type: research